A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

NCT06982859 · Recruiting

Last updated 2026-05-28

This study tests how the drug retatrutide affects insulin production and sensitivity in adults with type 2 diabetes.

Status Recruiting Currently enrolling participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 95 people Planned (estimated).

Who can join Ages 18–70 · all sexes

Timeline Started 2025-06 · est. completion 2026-11

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT06982859 ↗

Description as written by the study sponsor.

The primary objective of Study GZQG is to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment.

Treatments tested

Retatrutide also known as LY3437943 Drug

Administered SC
Semaglutide Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change from Baseline in Total Clamp Disposition Index (cDI) for Comparison of Retatrutide With Placebo
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Insulin Sensitivity
GLP-1 drugs	retatrutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06982859 ↗